{"commentary":{"count":89,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":50,"youtube":21,"podcast":16,"x_video":2},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03576417\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NIVOPOSTOP","nct_id":"NCT03576417","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nivopostop-nct03576417. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"NIVOPOSTOP","arms":[{"description":"100 mg/m2 of cisplatin on days 1, 22,43 of RT","label":"RT+ cisplatin","type":"ACTIVE_COMPARATOR"},{"description":"* 240 mg of nivolumab 3 weeks before RT-Cisplatin\n* 360 mg of nivolumab on days 1, 22,43 of -RT-cisplatin\n* 480 mg of nivolumab for maintenance","label":"RT+ cisplatin + nivolumab","type":"EXPERIMENTAL"}],"collaborators":["For Drug Consulting","Eurofins"],"completion_date":{"date":"2027-09","type":"ESTIMATED"},"conditions":["Squamous Cell Carcinoma of Head and Neck"],"enrollment":{"count":680,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Cisplatin","type":"DRUG"},{"name":"Nivolumab","type":"DRUG"},{"name":"RT","type":"RADIATION"}],"last_update":"2026-10-02","lead_sponsor":"Groupe Oncologie Radiotherapie Tete et Cou","official_title":"A Phase III Randomized Trial of Post-operative Adjuvant Nivolumab and Concomitant Chemo-radiotherapy in High-risk Patients With Resected Squamous Cell Carcinoma of Head and Neck","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2027-08","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Disease free survival","timeFrame":"3 years after the end of RT"}],"references":[{"citation":"Bourhis J, Auperin A, Borel C, Lefebvre G, Racadot S, Geoffrois L, Sun XS, Saada E, Cirauqui B, Rutkowski T, Henry S, Modesto A, Johnson A, Chapet S, Calderon B, Sire C, Malard O, Bainaud M, Da Silva Motta A, Thureau S, Pointreau Y, Blanchard P, Buiret G, Bozec L, Lopez S, Vanbockstael J, Bosset M, Greilsamer C, Daste A, Bruna A, N'Guyen F, Plana M, Iruarrizaga E, Temam S, Even C, Ruiz EP, Bert M, Karamouza E, Thariat J, Kazmierska J, Psyrri A, Mesia R, Tao Y. Nivolumab added to cisplatin and radiotherapy versus cisplatin and radiotherapy alone after surgery for people with squamous cell carcinoma of the head and neck at a high risk of relapse (GORTEC 2018-01 NIVOPOST-OP): a randomised, open-label, phase 3 trial. Lancet. 2026 Jan 24;407(10526):363-374. doi: 10.1016/S0140-6736(25)01850-1. Epub 2025 Dec 22.","pmid":"41448222","type":"DERIVED"}],"start_date":{"date":"2018-10-10","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck","url":"https://clinicaltrials.gov/study/NCT03576417"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nivopostop-nct03576417"}